Skip to content
Screener

Myriad Genetics MYGN U.S. — Revenue

Similar metrics at other companies

Titan Machinery logo
TITNU.S. — Revenue
$411.68M-9.8%
KBR logo
KBRU.S — Revenue
$1.03B-6.9%
FTI Consulting logo
FCNU.S. — Revenue
$596.35M+0.7%
PROCEPT BioRobotics Corporation logo
PRCTU.S. — Revenue
$83.42M+19.9%
Array Technologies, Inc. logo
ARRYU.S. — Revenue
$260.34M+61.8%
Monolithic Power Systems logo
MPWRU.S. — Revenue
$26.21M+44.6%

Other financials

Income statement

See full
Revenue$200.4M+2.3%
Gross profit$137.6M+2.5%
Operating income-$30.7M-5.9%
Net income-$34.1M-34,000%
EPS (diluted)-$0.36

Balance sheet

See full
Cash & equivalents$126.0M+24.8%
Total debt$211.5M+34.2%
Total equity$337.4M-52.1%
Total assets$673.7M-33.0%

Cash flow

See full
Operating cash flow-$15.7M+3.7%
CapEx$18.8M+181%
Free cash flow-$19.7M+65.1%

Valuation

See full
Market cap$311.82M-46.0%
Enterprise value$397.32M-38.7%
P/S0.4×-0.3×

Profitability

See full
Gross margin70%0.0pp
Operating margin-46.9%-88.3pp
Net margin-48.2%-72.9pp
FCF margin-17%

Returns & leverage

See full
Return on equity-76.7%-98.4pp
Debt / equity0.6×+0.4×
Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Myriad Genetics’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 6:05 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000899923-26-000038
(in millions)Three months ended March 31, 2026 / U.S.Three months ended March 31, 2026 / Ro WThree months ended March 31, 2026 / TotalThree months ended March 31, 2025 / U.S.Three months ended March 31, 2025 / Ro WThree months ended March 31, 2025 / Total
Cancer Care Continuum$106.8$13.4$120.2$101.4$14.2$115.6
Prenatal Health41.941.949.20.149.3
Mental Health38.338.331.031.0
Total revenue$187.0$13.4$200.4$181.6$14.3$195.9

Item 1. Financial Statements.

FAQ

What is Myriad Genetics's U.S. — revenue?
Myriad Genetics (MYGN) reported U.S. — revenue of $187M in Q1 2026.
How has Myriad Genetics's U.S. — revenue changed year-over-year?
Myriad Genetics's U.S. — revenue increased by 3.0% year-over-year, from $181.6M to $187M.
What is the long-term trend for Myriad Genetics's U.S. — revenue?
Over 4 years (2021 to 2025), Myriad Genetics's U.S. — revenue has grown at a 6.2% compound annual growth rate (CAGR), from $603.7M to $768M.
What does U.S. — revenue mean?
This metric represents the total gross sales generated from diagnostic testing services and products provided within the United States market. It serves as a primary indicator of the company's domestic market penetration, adoption of its molecular diagnostic panels, and the overall scale of its core commercial operations. Tracking this figure helps investors evaluate the performance of the company's primary geographic revenue stream and its ability to capture market share in the domestic healthcare sector.

Ask your AI about Myriad Genetics's u.s. — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude